Patents by Inventor Lee Edwards

Lee Edwards has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES
    Publication number: 20160068546
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 8, 2015
    Publication date: March 10, 2016
    Applicant: Novartis AG
    Inventors: Gurdip BHALAY, Emma BUDD, Graham Charles BLOOMFIELD, Stephen Paul COLLINGWOOD, Andrew DUNSTAN, Lee EDWARDS, Peter GEDECK, Catherine HOWSHAM, Peter HUNT, Thomas Anthony HUNT, Paul OAKLEY, Nichola SMITH
  • METHODS OF SYNTHESIZING AN OXIDANT AND APPLICATIONS THEREOF
    Publication number: 20160031732
    Abstract: Novel devices for synthesizing ferrate and uses thereof are described. One aspect of the invention relates to devices and systems for synthesizing ferrate at a site proximal to the site of use.
    Type: Application
    Filed: September 25, 2015
    Publication date: February 4, 2016
    Inventors: Lee Edward Ciampi, Luke J. Daly
  • APPARATUS AND METHOD FOR CANCELLING, REDUCING AND MODULATING NOISE SIGNAL AND FOR SIGNAL ENHANCING AND SIGNAL PROOFING
    Publication number: 20160019880
    Abstract: The embodiments herein provide an apparatus and method for cancelling signal noise. According to one embodiment, an apparatus for cancelling signal noise has a sensor or receiver to capture the undesirable signals. A transducer converts the energy of the captured signals and modulates the captured undesirable signals. A signal inverting circuit is connected to the transducer to generate the inverse of the captured undesirable signals by inverting the amplitude of the undesirable signal while maintain the frequency at the same level. The generated inverse of the undesirable signal transmitted by a transmitter is received by a receiver and output through a speaker so that the output inverse of the undesirable signal is combined with the undesirable signal to produce a desired signal environment.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 21, 2016
    Inventors: LANCE SAMUEL DAVIDSON, DENNIS LEE EDWARDS
  • Apparatus and method for cancelling, reducing and modulating noise signal and for signal enhancing and signal proofing
    Patent number: 9171537
    Abstract: The embodiments herein provide an apparatus and method for cancelling signal noise. According to one embodiment, an apparatus for cancelling signal noise has a sensor or receiver to capture the undesirable signals. A transducer converts the energy of the captured signals and modulates the captured undesirable signals. A signal inverting circuit is connected to the transducer to generate the inverse of the captured undesirable signals by inverting the amplitude of the undesirable signal while maintain the frequency at the same level. The generated inverse of the undesirable signal transmitted by a transmitter is received by a receiver and output through a speaker so that the output inverse of the undesirable signal is combined with the undesirable signal to produce a desired signal environment.
    Type: Grant
    Filed: December 12, 2009
    Date of Patent: October 27, 2015
    Assignee: UNR, LLC
    Inventors: Lance Samuel Davidson, Dennis Lee Edwards
  • Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives
    Patent number: 9139586
    Abstract: A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: September 22, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Emma Budd, Graham Charles Bloomfield, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith
  • Techniques for parallel business intelligence evaluation and management
    Patent number: 9123006
    Abstract: Techniques for parallel business intelligence and management are provided. Data is collected from a variety of disparate sources and from a variety of disparate network locations. The data is then filtered and normalized. Next, relationships between elements in the data are established and correlations are created between the elements. The elements are then tagged and integrated with other data of a distributed knowledge store to create customized business intelligence reports and customized data visualizations.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: September 1, 2015
    Assignee: Novell, Inc.
    Inventors: Stephen R Carter, Lee Edward Lowry, Vernon Roger Holm, Atul Mahajan
  • PYRAZINE DERIVATIVES AS ENAC BLOCKERS
    Publication number: 20150224098
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: April 20, 2015
    Publication date: August 13, 2015
    Inventors: Gurdip BHALAY, Lee EDWARDS, Catherine HOWSHAM, Peter HUNT, Nichola SMITH
  • PORTABLE LOCK-DOWN SYSTEM
    Publication number: 20150225989
    Abstract: A portable lock down device having at least one end encircling or grasping a door or window handle or other fixed object on the door, a cable or other flexible material extending to a loop or cable attachment device allowing easy attachment and detachment to the primary fixed eyebolt via a spring coupling device, the lock-down system passing through an eyebolt or collapsible ring adjacent to the door's edge, coupling to a primary eyebolt mounted in the wall and out of reach of an intruder so as to provide classroom security.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Inventors: Celisa Jeanette Edwards, Curtis Lee Edwards
  • Portable Lock-down System
    Publication number: 20150204122
    Abstract: A portable lock-down device, comprising of a loop or clasping device encircling or grasping a door handle or other fixed object on the door, a cable or other flexible material extending to a loop or cable attachment device allowing easy attachment and detachment to the fixed primary eyebolt via a spring coupling device, said portable lockdown device passes through an eyebolt or collapsible ring adjacent to the doors edge, coupling to the primary eyebolt, mounted in the wall, well out of reach of an intruder, provides classroom security.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 23, 2015
    Inventors: Curtis Lee Edwards, Celisa Jeanette Edwards
  • N-substituted heterocyclyl carboxamides
    Patent number: 9056867
    Abstract: A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 16, 2015
    Assignee: NOVARTIS AG
    Inventors: Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Darren Mark LeGrand, Roger John Taylor
  • Techniques for instantiating and configuring projects
    Patent number: 9058579
    Abstract: Techniques for project management instantiation and configuration are provided. A master project includes policy directives that drive the dynamic instantiation and configuration of resources for a project. The resources are instantiated and configured on demand and when resources are actually requested, in response to the policy directives.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: June 16, 2015
    Assignee: Novell, Inc.
    Inventors: Michel Shane Simpson, Volker Gunnar Scheuber-Heinz, Lee Edward Lowry, Stephen R Carter
  • Techniques for mapping and managing resources
    Patent number: 9052960
    Abstract: Techniques for mapping and managing resources are presented. Hardware capacity and information is collected over multiple processing environments for hardware resources. The information is mapped to logical business resources and resource pools. Capacity is rolled up and managed within logical groupings and the information gathering is managed via in-memory and on-file caching techniques.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: June 9, 2015
    Assignee: NetIQ Corporation
    Inventors: Lee Edward Lowry, Michael Joseph Sorensen
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9050339
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • Heterocyclic compounds for the treatment of CF
    Patent number: 9034879
    Abstract: The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 19, 2015
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Rebecca Butler, Stephen Paul Collingwood, Edward Charles Hall, Lee Edwards, Darren Mark Legrand, Katrin Spiegel
  • Techniques for project lifecycle staged-based access control
    Patent number: 8959578
    Abstract: Techniques for project lifecycle staged-based access control are provided. Access control rights are defined for a stage of a project's lifecycle. As requestors transition to the stage, the access control rights are enforced on top of any existing security restrictions. In an embodiment, selective resources are not visible to requestors within the stage in response to the access control rights.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: February 17, 2015
    Assignee: Apple Inc.
    Inventors: Michel Shane Simpson, Volker Gunnar Scheuber-Heinz, Lee Edward Lowry, William Street
  • Pyridine and Pyrazine derivative for the Treatment of CF
    Publication number: 20150045364
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Urs BAETTIG, Kamlesh BALA, Emma BUDD, Lee EDWARDS, Catherine HOWSHAM, Glyn Alan HUGHES, Darren Mark LEGRAND, Katrin SPIEGEL
  • Anti-IL-23 Antibodies
    Publication number: 20140363444
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 11, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rachel Rebecca BARRETT, Keith CANADA, Katrina Mary CATRON, Robert COPENHAVER, Lee Edward Frego, Ernest Lee Raymond, Sanjaya SINGH, Xiangyang ZHU
  • Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders
    Patent number: 8901134
    Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: December 2, 2014
    Assignee: Novartis AG
    Inventors: Graham Charles Bloomfield, Ian Bruce, Brian Cox, Lee Edwards, Judy Fox Hayler, Catherine Howsham
  • N-Substituted Heterocyclyl Carboxamides
    Publication number: 20140323485
    Abstract: A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 14, 2012
    Publication date: October 30, 2014
    Applicant: NOVARTIS AG
    Inventors: Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Darren Mark LeGrand, Roger John Taylor
  • Pyrazine compounds as PI3 kinase inhibitors
    Patent number: 8846687
    Abstract: The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar?, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventors: Ian Bruce, Emma Budd, Lee Edwards, Catherine Howsham